Arthritis Clinical Trials in Cleveland, OH

24 recruiting studies within 50 miles

Phase

Trial	Phase	Sponsor	Dist.
Observational Study of Pediatric Rheumatic Diseases: The CARRA Registry	—	Duke University	<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have Not Taken Biologic Medicines	Phase 3	Takeda	<1 mi
Multi-Vendor Multi-Site Novel Accelerated MRI Relaxometry	—	Xiaojuan Li	<1 mi
A Study of Zasocitinib in Adults With Psoriatic Arthritis Who Have or Have Not Been Treated With Biologic Medicines	Phase 3	Takeda	<1 mi
Improving Total Knee Arthroplasty Dissatisfaction Through a Personalized Approach Focusing on PROMs Phenotypes	N/A	The Cleveland Clinic	<1 mi
Persona OsseoTi Keel Compatibility Study (Total Knee Arthroplasty)	—	Zimmer Biomet	<1 mi
RA-PRO PRAGMATIC TRIAL	Phase 3	University of Alabama at Birmingham	<1 mi
A Study to Evaluate the Drug Levels, Efficacy, and Safety of Deucravacitinib (BMS-986165) in Pediatric Participants With Juvenile Psoriatic Arthritis	Phase 3	Bristol-Myers Squibb	<1 mi
Preventing Injured Knees From osteoArthritis: Severity Outcomes	Phase 2	Brigham and Women's Hospital	<1 mi
A Study to Assess Adverse Events, Change in Disease Activity, and How the Drug Moves Through the Body in Children With Juvenile Psoriatic Arthritis (jPsA) Receiving Subcutaneously Injected Risankizumab or Adalimumab	Phase 3	AbbVie	<1 mi
Persona Revision Knee System Outcomes	—	Zimmer Biomet	<1 mi
Study to Evaluate the Pharmacokinetics (PK), Safety and Tolerability up to 6 Years of Intravenous (i.v.) Secukinumab in Pediatric Participants With Juvenile Psoriatic Arthritis (JPsA).	Phase 1	Novartis Pharmaceuticals	<1 mi
A Multicenter, Postmarket Surveillance Study of Subjects With the Canary canturioTM te Tibial Extension	—	Canary Medical	<1 mi
A Study of CC-97540, CD-19-Targeted Nex-T CAR T Cells, in Participants With Severe, Refractory Autoimmune Diseases (Breakfree-1)	Phase 1	Juno Therapeutics, Inc., a Bristol-Myers Squibb Company	<1 mi
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases	Phase 2	Amgen	<1 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis Naive to Biologic Disease-Modifying Antirheumatic Drug	Phase 3	MoonLake Immunotherapeutics AG	11 mi
Study of Targeted Therapies for the Treatment of Adult Participants With Active Psoriatic Arthritis	Phase 2	AbbVie	11 mi
Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis	Phase 3	Sun Pharmaceutical Industries Limited	11 mi
A Study to Evaluate Different Targeted Therapies for Patients With Rheumatoid Arthritis	Phase 2	AbbVie	11 mi
A Study to Investigate Effectiveness of Tirzepatide Following Initiation of Ixekizumab in Participants With Active Psoriatic Arthritis and Overweight or Obesity in Clinical Practice (TOGETHER AMPLIFY-PsA)	Phase 4	Eli Lilly and Company	11 mi
A Study to Evaluate the Efficacy and Safety of JNJ-88545223 for the Treatment of Participants With Active Psoriatic Arthritis	Phase 2	Janssen Research & Development, LLC	11 mi
Evaluation of Sonelokimab in Patients With Active Psoriatic Arthritis and Anti-TNFα Inadequate Response	Phase 3	MoonLake Immunotherapeutics AG	11 mi
Exactech Shoulder Post Market Clinical Follow-up Study	—	Exactech	30 mi
The Myelin Disorders Biorepository Project	—	Children's Hospital of Philadelphia	30 mi

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.